title: Downstream Regulatory Element Antagonist Modulator (DREAM), a target for anti-thrombotic agents.
abstract: Circulating platelets participate in the process of numerous diseases including thrombosis, inflammation, and cancer. Thus, it is of great importance to understand the underlying mechanisms mediating platelet activation under disease conditions. Emerging evidence indicates that despite the lack of a nucleus, platelets possess molecules that are involved in gene transcription in nucleated cells. This review will summarize downstream regulatory element antagonist modulator (DREAM), a transcriptional repressor, and highlight recent findings suggesting its novel non-transcriptional role in hemostasis and thrombosis.
authors.affiliation: Department of Pharmacology, University of Illinois-Chicago College of Medicine, USA. Electronic address: thromres@uic.edu.
authors.forename: Jaehyung
authors.initials: J
authors.lastname: Cho
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D051605:Kv Channel-Interacting Proteins / Q000378:metabolism*; D013927:Thrombosis / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D005343:Fibrinolytic Agents; D051605:Kv Channel-Interacting Proteins
keywords: DREAM; Platelet activation; Thrombosis and hemostasis